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ABSTRACT
HMGA proteins are not translated in normal human
somatic cells, but are present in high copy numbers
in pluripotent embryonic stem cells and most neo-
plasias. Correlations between the degree of malig-
nancy, patient prognostic index and HMGA levels
have been firmly established. Intriguingly, HMGA2
is also found in rare tumor-inducing cells which
are resistant to chemotherapy. Here, we demon-
strate that HMGA1a/b and HMGA2 possess intrinsic
dRP and AP site cleavage activities, and that lysines
and arginines in the AT-hook DNA-binding domains
function as nucleophiles. We also show that HMGA2
can be covalently trapped at genomic abasic sites in
cancer cells. By employing a variety of cell-based
assays, we provide evidence that the associated
lyase activities promote cellular resistance against
DNA damage that is targeted by base excision repair
(BER) pathways, and that this protection directly
correlates with the level of HMGA2 expression.
In addition, we demonstrate an interaction between
human AP endonuclease 1 and HMGA2 in cancer
cells, which supports our conclusion that HMGA2
can be incorporated into the cellular BER machin-
ery. Our study thus identifies an unexpected role for
HMGA2 in DNA repair in cancer cells which has
important clinical implications for disease diagnosis
and therapy.
INTRODUCTION
Mammalian high mobility group AT-hook (HMGA)
proteins are non-histone chromatin factors encoded by
two genes, HMGA1 and HMGA2. Alternative mRNA
splicing gives rise to at least four protein isoforms which
can be chemically modiﬁed (1–3). HMGA proteins are
characterized by small sizes, an acidic C-terminal tail
and the presence of three individual DNA-binding
domains, so-called AT-hooks. Each hook is composed
of nine amino acids containing an invariant RGRP
repeat ﬂanked by lysine and arginine residues. NMR anal-
yses indicated that this domain is unstructured in solution
and adopts a crescent-shaped conﬁguration upon binding
to the minor groove of short stretches of AT-rich
DNA (4).
The biological roles of HMGA2 were initially studied in
the mouse where it is expressed in embryonic stem (ES)
cells and during embryogenesis. The protein is classiﬁed as
a transcriptional regulator that modulates local chromatin
structure near promoters critical for cell growth, sperma-
togenesis and adipogenesis. HMGA2 knock-out mice
exhibit a pygmy phenotype with greatly reduced fat
tissues, and male mice are infertile (5–8). In contrast,
tissue-speciﬁc over-expression of full-length or ubiquitous
expression of a truncated protein lacking the C-terminal
tail resulted in gigantism, lipomatosis and mesenchymal
tumors (9,10).
In humans, HMGA2 is not detected in normal adult
somatic cells, but it is found in some fetal tissues (11).
We have shown recently that HMGA2 remains associated
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human ES (hES) cells, and that expression levels are fur-
ther elevated during a short time window in embryoid
bodies (12). In addition, we demonstrated that HMGA2
is involved in the regulation of key human genes linked to
mesenchymal cell lineage diﬀerentiation, adipogenesis and
hES cell proliferation control (13).
Besides these critical roles in early mouse and human
development, clinicians have known for some time that
high HMGA protein levels are associated with most
malignant human neoplasias, such as breast cancer, sar-
comas, pancreas, oral squamous cell carcinomas and lung
cancer (14–18). In addition, HMGA2 rearrangements are
frequently found in benign tumors of mesenchymal origin
(19–21). In fact, the HMGA genes are the only known
proto-oncogenes coding for DNA-architectural chromo-
somal proteins consistently over-expressed in nearly all
types of naturally occurring cancers. Their expression
level correlates directly with the degree of malignancy
and metastatic potential (3,21–23). In line with these
observations, recent microarray analyses showed that
both HMGA genes belong to a small class of genes whose
expression is critical to the cancer phenotype in cells that
carry two key oncogenic mutations in p53 and Ras (24).
The miRNAs let-7 and miRNA-98 are directly involved
in the regulation of HMGA2 during oncogenic transfor-
mation (25,26). Interestingly, the let-7/HMGA2 linkage
was recently identiﬁed as a candidate signature of cancer
stem cells derived from primary human cancer tissues.
These cells are resistant to a therapy that introduces chem-
ical modiﬁcations of DNA bases, such as oxidation
(27–29). There is evidence that HMGA2 is involved in
cancer stem cell diﬀerentiation and proliferation control
(27), but due to the pleiotropic functions of HMGA2 as a
DNA-architectural chromatin factor; the molecular
mechanism(s) which connect the let-7/HMGA2 linkage
with chemotherapy-resistant cancer stem cells remain
elusive. It is noteworthy here that the presence of
HMGA1 is also functionally linked to chemoresistance
of certain types of human carcinomas (30).
During our studies of DNA lyase activities associated
with proteins belonging to the Escherichia coli DNABII
family of DNA-binding proteins (unpublished result), we
discovered that recombinant human HMGA proteins eﬃ-
ciently cleaved DNA containing apurinic/apyrimidinic
(AP) sites in vitro. We present here a biochemical analysis
of these associated lyase activities and demonstrate with
cell-based experiments that HMGA2 is directly involved
in base excision repair (BER) and protects cancer cells
from DNA-damage that occur, for example, during
chemotherapy. We discuss our ﬁndings with respect to
genome stability in both cancer and hES cells, and point
out important immediate clinical implications for cancer
diagnosis and therapy.
MATERIALS AND METHODS
DNA substrates and proteins
Oligonucleotides (31-mers) containing uracil were
obtained from AitBiotech, and
32P-labeled either at the
50 end with T4 polynucleotide kinase and [g
32P]ATP
(Perkin Elmer) or at the 30 end with Klenow Fragment
(30-50 exo
 ) and [a
32P]ddATP. Double-stranded substrates
were prepared by annealing the
32P-labeled uracil contain-
ing 31-mer with its complementary strand at a 1:1.5 stoi-
chiometry in a buﬀer containing 20mM Tris–HCl (pH
7.4), 50mM NaCl. The AP site was generated by incubat-
ing the double-stranded DNA with an excess amount of
uracil DNA glycosylase for 1h at 378C. The substrate for
dRP lyase is the 30-
32P-labeled 31-mer containing an AP
site which was pre-incubated with an excess of E. coli
endonuclease IV, thus generating a 30 end-labeled fragment
(18-mer) containing a 50phosphodexoyribosyl moiety.
HMGA2 was expressed from pET17b-hHMGA2-His as
previously described (12) and HMGA1a and b proteins
were expressed from pET21a-HMGA1a/b-His vectors
(a kind gift of Dr R. Hock). All HMGA proteins were
expressed in E. coli BL21 (DE3) pLys strain harboring
previously mentioned plasmids. Bacteria were grown in
LB medium to OD600nm > 0.8 and induced with 0.1mM
IPTG (1st Base) for 4h. Cells were harvested by centri-
fugation (10000 g) for 20min. Cell pellets were dis-
solved in Lysis buﬀer [300mM NaCl, 10mM
Imidazole, 50mM Na Phospate pH 8.0, protease inhibi-
tor cocktail (Roche)] and sonicated. The lysate was cen-
trifuged at 48500 g for 1h. Cleared lysate was loaded
on a HisTrap column (GE) and equilibrated with the
same buﬀer. The proteins were eluted in a linear gradient
with buﬀer A (300mM NaCl, 250mM Imidazole, 50mM
Na phosphate pH 8.0) between 100–150mM Imidazole.
The protein containing fractions were pooled together
and diluted with 50mM Na phosphate buﬀer pH 7.3
to have a ﬁnal concentration of 100mM NaCl. The pro-
tein was further puriﬁed by cation exchange chromato-
graphy on a HiTrap SP HP column (GE) equilibrated
with buﬀer B (50mM Na Phosphate pH 7.3, 100mM
NaCl, 5mM EDTA). The protein was eluted running a
linear gradient to 100% buﬀer C (same as B but 1M
NaCl) at around 300mM NaCl. Protein containing frac-
tions were conﬁrmed via 15% reducing SDS–PAGE and
Maldi-mass spectrometry. The puriﬁed proteins were dia-
lysed against 50mM Tris pH 8.0. Proteins were ali-
quoted, ﬂash frozen and stored at  808C. The yield
ranged from 2–4mg/l culture. Gel images were scanned
using a Bio-Rad Quantity One GS-800 calibrated
densitometer.
In vitro lyase assays
DNA cleavage assays employing a 5kb supercoiled
plasmid (pCMV-Int) were performed with either full-
length HMGA2 or a peptide comprising AT-hook 3
(KRPRGRPRK). A 50ml reaction contained either
9.18nM abasic or normal DNA substrate (control), was
incubated in a buﬀer made up of 25mM Tris–HCl, pH
7.5; 2mM EDTA; 100mM NaCNBH3 with 4.92mM
HMGA2 at 378C for 40min. NaCl (100mM) was used
in place of NaCNBH3 in controls. Reactions were
quenched by 2% SDS ﬁnal concentration and heated at
658C for 15min. Samples were puriﬁed by Qiagen
QIAquick PCR Puriﬁcation Kit. For each sample,
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Cleavage was analyzed by agarose gel electrophoresis. To
detect HMGA2–DNA complexes, DNA was subsequently
transferred to a Nylon membrane. The presence of
HMGA2 was detected by immunoblotting using anti-
HMGA2 polyclonal antibodies (S15, Santa Cruz) at a
1:500 dilution, and bovine anti-goat HRP-conjugated sec-
ondary antibodies (Santa Cruz) at a 1:5000 dilution.
The nature of the 50 and 30 termini generated by
HMGA2 on DNA containing an AP site was determined
by comparing the electrophoretic mobility of products
generated by HMGA2 with those created by E. coli
enzymes Endo III, Endo IV, or Fpg. The AP lyase activity
was assayed in a 10ml reaction containing 1  reaction
buﬀer (10mM Tris–HCl, pH 7.5; 1mM EDTA; 50mM
KCl) and 1.5mMo f5 0-
32P-labeled 31-mer-AP substrate
plus 15mM of HMGA proteins or hook 3. For control
reactions, eight units of Endonuclease III and FPG
(NEB) was used. The Endocnuclease IV (Fermentas) reac-
tion had two units in a 10ml reaction. Additionally the
HMGA and hook 3 reactions were treated afterwards
for 15min with Endo IV. Reactions were stopped after
30min by the addition of 10ml loading buﬀer (90% for-
mamide, 1mM EDTA, 0.1% xylene cyanol and 1% SDS)
and heated at 708C for 10min. Total 5ml of the reaction
mixture were loaded onto a 12.5% denaturing polyacry-
lamide gel. For quantiﬁcation, a 4% acrylamide-stacking
gel was prepared and the substrate concentration was
0.5mM. Radioactive bands were quantiﬁed with a
Quantity one FX scanner (Bio-Rad).
In order to identify the nucleophile(s), various AT-hook
3 mutant peptides, as indicated in Figure 3D, were pur-
chased from Research Biolabs or produced in-house.
Each sample contained 1  reaction buﬀer, 0.5mM peptide
and 0.33mM of the 31-mer, 50-Cy5dye-labeled uracil-
containing substrate (AIT Biotech), pretreated with
UDG to generate the AP site as described above. Then,
10ml reactions were incubated at 378C for 45min and
stopped by adding 10ml of gel-loading buﬀer (90%
formamide, 1mM EDTA, 10% glycerol and 1% SDS).
An amount of 5ml each reaction were heated to 708C for
10min and loaded on a 15% denaturing PAGE. Gels were
scanned using a Typhoon Variable Mode Imager (GE)
and data analyzed using Image Quant TL software
(GE). The trapping experiments were performed identi-
cally to the AP cleavage assays, except that 50mM of
NaCNBH3 (ﬁnal conc.) was included before the reaction
was initiated by the addition of substrate.
The dRP lyase activity of HMGA proteins and hook 3
was assayed as described previously (31) with the follow-
ing modiﬁcations: The 50-dRP moiety was stabilized by the
addition of O-benzyl hydroxylamine (BA) (Sigma) prior
to electrophoresis. The formation of 50-BA-dRP also
allows for a better separation on a more conventional
16% denaturing polyacrylamide gel. The dRP lyase sub-
strate was generated by preincubation of 30-labeled 31-mer
containing an AP site with two units of E. coli Endo IV for
15min in 1  reaction buﬀer and 0.5mM DNA. The dRP
lyase activity was assayed by addition of 5mM protein
and incubated for 15min at 378C. The reaction was
stopped by the addition of 1ml 1M BA, followed by
further incubation for 10min. Modiﬁcation of 50-dRP by
BA was completed within 1min. Total 10ml of loading
buﬀer (90% formamide, 1mM EDTA, 0.1% xylene
cyanol, 10% glycerol and 1% SDS) was added and
heated at 708C for 10min. An amount of 3ml was
loaded onto a 16% denaturing polyacrylamide gel.
Radioactive bands were quantiﬁed with a Quantity one
FX scanner (Bio-Rad).
Generation of HMGA2 cell lines
The hHMGA2c-DNA was cloned from mRNA isolated
from hES2 cells (12) and a histidine aﬃnity tag aﬃxed
at the C-terminus by RT–PCR using primers
(HMGA2Kpn1F) 50-CGG GGT ACC ATG AGC GCA
CGC GGT GAG GGC-30 and (HMGA2HisEcoR1R)
50-GGA ATT CTT ACT AGT GGT GGT GGT GGT
GGT GAG CGC TGT CCT CTT CGG CAG ACT
C-30. The expression vector pEF1-hHMGA2-His-Neo
was constructed by inserting the hHMGA2 coding
sequence into pEF1-mycA-Neo (Invitrogen) using KpnI
and EcoRI (New England Biolabs). DNA constructs
were conﬁrmed by sequencing. pEF1-hHMGA2-His-Neo
was transfected into HeLa (ATCC No. CCL-2) cells using
lipofectamine (Invitrogen) and into A549 (ATCC No.
CCL-185) cells via electroporation. Neomycin resistant
cells were selected at 500mg/ml G418 and individual
colonies were picked and tested for HMGA2 expression
by western analysis.
Immunoblotting
Harvested cells were lysed in a NP40 buﬀer containing 1%
SDS. Lysates were sonicated on ice (5W; 10 3s). Protein
concentrations were determined with the BCA protein
Assay Kit (Pierce Biotechnology). Lysates equivalent to
15mg of total protein (or 1 10
5 cells) were analyzed
through 15% SDS–PAGE and transferred to PVDF mem-
brane with 20mm pore size (Bio-Rad). The blot was
blocked with 5% nonfat milk and incubated with goat
polyclonal antibody against HMGA2 (S15, Santa Cruz)
at a 1:500 dilution. Bound antibodies were detected by
secondary anti-goat HRP-conjugated antibodies (Santa
Cruz) and revealed with Lumi-light (Roche Diagnostic).
b-actin was employed as an internal standard using mono-
clonal antibodies raised against human b-actin (Sigma).
Trapping of HMGA2 on genomic DNA
For in vitro trapping of HMGA2 on genomic DNA
isolated from cells challenged with low pH, A549 cells
were ﬁrst treated on culture dishes with pH 2 in PBS, or
physiological PBS as control, for 10min at 378C, followed
by a wash with PBS. Cells were harvested in the same
buﬀer and genomic DNA was puriﬁed with DNeasy
Blood & Tissue Kit (Qiagen). An amount of 3mg
HMGA2 was incubated with 1mg of DNA in a buﬀer
containing 25mM Tris–HCl, pH 7.5, 2mM EDTA and
100mM NaCNBH3 at 378C for 40min. DNA was puriﬁed
with QIAquick PCR Puriﬁcation Kit (Qiagen) and spot-
ted onto PVDF membrane for HMGA2 detection by
immunoblotting. For in vivo trapping, adherent transgenic
A549-HMGA2 (1.6) cells were ﬁrst treated with PBS at
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ologic PBS containing 100mM NaCNBH3 (Sigma), or
100mM NaCl as a control. Cells were harvested in the
same buﬀers and genomic DNA puriﬁed with DNeasy
Blood & Tissue Kit (Qiagen). Puriﬁcation involved
SDS–based lysis with a short protease treatment for
10min at 708C. NaCNBH3 or NaCl was present during
elution, and the same amount of genomic DNA was spot-
ted onto a PVDF membrane for HMGA2 detection.
Cell survival assays
To challenge cells with low pH, cell lines were treated with
PBS (pH 2) at 378C for 6min. HeLa and the respective
transgenic cell lines were challenged at pH 3. Cells were
allowed to recover under normal culture conditions for
24h before harvest. Cells were treated with 100mM
hydroxyurea (Sigma) under culture conditions for 48h
before harvest. To challenge cells with paclitaxel
(Sigma), A549 cell lines were treated with 50nM paclitaxel
for 48h before harvest, while HeLa cell lines were treated
with 20nM paclitaxel for the same period. A549 cell lines
were treated with 20mM cisplatin (Sigma) for 48h before
harvest, and HeLa cell lines were exposed to 20mM cis-
platin for 24h. To challenge cells with MMS (Sigma),
A549 cell lines were treated with MMS for 1h followed
by a recovery period for 48h before harvest. In some
experiments, we added 5mM BA (O-benzyl hydroxyla-
mine) to the cell culture media throughout the recovery
period. HeLa cell lines were treated with 4mM MMS.
After recovery, cells were trypsinized and harvested,
including those from the culture media and wash buﬀer.
Cells were collected at room temperature by centrifuga-
tion at 600 g for 3min, washed once with PBS and
stained with Annexin-V ﬂuorescence and Propidium
Iodide (PI) using Annexin-V-FLUOS Staining Kit
(Roche) according to the manufacturer’s protocol. Cells
were analyzed by FACS Calibur (BD). Cells with negative
staining for both Annexin-V and PI were counted as life
cells; those with positive staining for both markers were
qualiﬁed as necrotic cells; and those with positive staining
for Annexin-V, but negative staining for PI, counted as
apoptotic cells.
In MMS challenge experiments with transient HMGA2
transfected cells, 5 10
4 A549 or HeLa cells were seeded in
each well of a 24-well plate before 1mg of pEF1-
HMGA2-His vector was transfected. Forty-eight hours
after transfection, cells were treated with various amount
of MMS (0.5 and 1mM for A549 cells; 0.2 and 0.5mM for
HeLa cells) for 1h. Cells were then recovered for 24h
before being trypsinized. Total 2000 cells from each
sample were counted and plated in a 10cm culture dish
and left untouched until single cell colonies were formed
and become large enough to count. CMV-EGFP cells were
used as controls in these experiments, and transfection eﬃ-
ciency was determined before MMS treatment by ﬂow
cytometry. Each experiment was performed in triplicate.
Protein co-affinity precipitation
A total of 2 10
7 of each A549, A549-HMGA2 (1.3),
HeLa and HeLa-HMGA2 (P2) cells were collected and
lysed with 0.5ml native lysis buﬀer containing 50mM
Tris–Cl, pH 8.0, 150mM NaCl, 0.1% NP-40, 2mM
DTT, 5% glycerol and protease inhibitors (Roche).
Sonication was applied to each lysate at output power of
2W for 15 5s in iced water bath. Each sample was
topped up to 1ml with lysis buﬀer and centrifuged at
16100 g for 10min at room temperature, and the super-
natant was incubated overnight rolling at 48C with 50ml
Ni+ sepharose beads (GE Healthcare) which was pre-
incubated with lysis buﬀer containing 1% BSA. An
amount of 50ml supernatant was kept as cell lysate con-
trol. The beads were collected at 100 g for 2min at room
temperature and washed with lysis buﬀer for 4 10min
with rolling. Elution was done with 50ml of buﬀer contain-
ing 20mM NaH2PO4,2 0 m MN a 2HPO4, 500mM NaCl
and 500mM Imidazole, pH 8.0. The eluted material,
together with the cell lysate controls were then analyzed
on SDS–PAGE and later subjected to western blotting
analysis for HMGA2 and APE1. Detection of HMGA2
was done as described above, and detection of APE1 was
performed using rabbit polyclonal antibody against APE1




6cells/ml) were collected in DMEM without
serum. An amount of 100ml cell suspension were mixed
with 0.1mM MMS (30ml of 10mM MMS in DMEM) and
2.87ml serumfree medium for 2h at 378C. Cells were col-
lected, washed in PBS, and resuspended in 10ml PBS. The
standard alkaline assay (pH > 13) for detecting DNA
damage in single cells was performed according to the
method developed by Singh (32), with minor modiﬁca-
tions. Brieﬂy, 10
5cells/10ml cell suspension in PBS was
mixed with 50ml of 0.7% low melting point agarose
(LMP; Fulka), layered on a microscopic slide previously
coated with 1% normal melting point agarose (NMA;
Bio-Rad). After the agarose solidiﬁed, slides were
immersed in pre-chilled lysis solution (2.5M NaCl,
100mM EDTA, 10mM Tris, pH 10 and 1.5% Triton
X-100) for 1h at 48C. Slides were then washed with dis-
tilled water and incubated in a horizontal gel electrophor-
esis tank with fresh alkaline electrophoresis buﬀer
(300mM NaOH, 1mM EDTA, pH 13.5) for 40min at
48C. Electrophoresis was conducted at 48C for 30min at
25V (0.8V/cm) and 300mA. Once completed, the gels
were neutralized by three washes with 0.4M Tris–HCl,
pH 7.5 for 5min each. After neutralization, the agarose
gels were dehydrated by immersing the slides in absolute
ethanol for 5min, and stained overnight with DAPI
(500ng/ml) in PBS. Images were obtained at 400-fold
magniﬁcation using a ﬂuorescence microscope (Olympus).
Fluorescence was visualized using a chroma ﬁlter at
excitation 385nm and emission 450nm. Slides were ana-
lyzed by Comet Score Version 1.5 Software (http://
www.autocomet.com/products_cometscore.php). DNA
damage was quantiﬁed by Olive tail moment as introduced
by Olive (33), which is deﬁned as multiplying the total
intensity of the comet tail by the tail length, measured
from the centre of the comet head.
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HMGA2 has an intrinsic AP lyase activity
Our initial screen for AP lyase activities employed super-
coiled plasmids which contained an undeﬁned number
of AP sites that resulted from depurination during expo-
sure to acidic pH. Incubation with HMGA2 converted
the majority of supercoiled AP plasmids into the open
circular form, while control plasmids remained super-
coiled (Figure 1A). If the observed cleavage of AP site-
containing plasmids was due to an associated AP lyase
activity, Schiﬀ0base intermediates should have been
generated by nucleophilic attack of a primary amine
group to the aldehyde form of the AP site. Therefore,
we tested whether covalent DNA–HMGA2 complexes
could be trapped by the reducing agent NaCNBH3 (31).
HMGA2 was incubated either with AP site plasmids or
control substrates under trapping or non-trapping condi-
tions, and reactions were stopped with SDS and heated to
658C. DNA was resolved by agarose gel electrophoresis
and transferred to a nylon membrane. Western blotting
revealed that HMGA2 could be trapped during incuba-
tion only on AP plasmids, and that the protein could be
detected on both the supercoiled and relaxed DNA forms,
as expected for substrates with multiple AP sites
(Figure 1B).
Since the three independent AT-hooks of HMGA2 are
mainly composed of arginine and lysine residues which
penetrate deeply into the minor DNA grove, and are
nearly identical in amino-acid sequence (4), we hypothe-
sized that the primary amine(s) responsible for the cleav-
age activity likely resided within DNA-binding domains.
We employed a short peptide comprising the third AT-
hook of HMGA2, which exhibits the lowest DNA-binding
aﬃnity, and incubated it with AP site or control plasmids.
As observed with the full-length protein, the peptide
cleaved only AP site-containing plasmids (Figure 1A).
These results indicate that a nucleophile(s) that attacks
the C01 of deoxyribose at AP sites could reside within
the AT-hooks.
The ﬁrst two AT-hooks are identical in HMGA1 and
HMGA2 proteins, which led us to test whether the two
main HMGA1 isoforms generated by alternative splicing,
i.e. HMGA1a and HMGA1b, also exhibit AP lyase activ-
ities that can be trapped by NaCNBH3 (Figure 1C).
Furthermore, data obtained with mass spectrometry on
trapped HMGA2–plasmid complexes strengthen our con-
clusion that the primary amine(s) responsible for the lyase
activity resides in the AT-hook (Supplementary Figure 1).
Our ﬁnding that HMGA1 and HMGA2 can be cova-
lently trapped on AP substrates by NaCNBH3 indicated
that the AP lyase-associated cleavage reaction employed b
elimination (34). Hence, in order to determine the chemi-
cal nature of DNA ends generated by HMGA proteins
and the eﬃciency of AP site cleavage, we employed a
32P-labeled double-stranded 31-mer oligonucleotide as
substrate, which contained a single AP site (Figure 2A).
The results show that incubation of puriﬁed HMGAs or a
peptide comprising HMGA2 AT-hook 3 with the sub-
strate generated cleavage products, which exhibit the
same electrophoretic mobility as those produced by
endonuclease III, an AP lyase derived from E. coli
(Figure 2B and C, lanes 2–6). In addition, products
generated by HMGA2 diﬀered from those obtained
with E. coli enzymes AP endonuclease IV, which
produces 30OH ends, and from those obtained with
Figure 1. HMGA2 acts as an AP lyase on abasic supercoiled DNA.
(A) Cleavage assay with full-length HMGA2 or a peptide comprising
the third AT-hook with abasic supercoiled (sc) DNA. AP site cleavage
converts the topology of sc DNA into the open circular (oc) form. Note
that depurinated input DNA is mostly sc and does not change during
incubation without HMGA2. (B) Detection of in vitro trapped
HMGA2 on AP site plasmid DNA using western blotting. The posi-
tions of HMGA2–DNA complexes detected on the western blot mem-
brane are marked by arrows. (C) Cleavage and in vitro trapping assay
with HMGA1a, HMGA1b and HMGA2 on abasic sc DNA.
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ates 30 phosphates during AP site cleavage (Figure 2C,
lanes 7 and 12, respectively). Importantly, when we sub-
sequently incubated
32P-labeled products generated by
HMGA proteins with AP endonuclease IV, their mobility
was increased. This indicates that the 4-hydroxy-2-
pentenal moiety generated by HMGA’s AP site cleavage
activity had been removed from the 30 end (Figure 2C,
compare lanes 3–6 with lane 8–11). Incubation with
increasing protein/DNA ratios and quantiﬁcation of
cleavage established that all 3 HMGA proteins have
similar activities, which was higher as compared to the
isolated AT-hook 3 from HMGA2 (Figure 2D).
Nucleophiles responsible for AP site cleavage reside
within AT-hooks
Our data indicate that HMGA proteins possess AP site
cleavage activity which involves b elimination. This activ-
ity resides within the DNA-binding domain, the AT-hook
3. In an attempt to identify the nucleophile(s) within the
hook, we employed a series of peptides according to the
peptide sequence of the AT-hook 3 in which each of
the lysine or arginine residues was individually replaced
by glycine and tested them for cleavage activity using the
same 31-mer substrate which had been 50-Cy5dye-labeled.
The result of a representative experiment showed that
compared with the unmodiﬁed hook 3, substitution of
the lysine at position one (K1) substantially reduced cleav-
age from 25% to about 5.8% (Figure 3A). With the excep-
tion of the arginine at position eight (R8), substitutions of
arginines R2, R4 and R6 also led to substantially dimin-
ished cleavage activities (Figure 3A). The importance of
arginines for AP site cleavage was further demonstrated
with two additional peptides in which either all arginines
or lysines were replaced by alanines. While the latter still
catalyzed residual cleavage (3.3%), the activity of these
peptides lacking arginines was reduced to that observed
with a control peptide representing the linker connecting
AT-hook 1 and 2 in HMGA2 (Figure 3A).
These results suggest that the lysine at the N-terminus
of the hook might be the crucial nucleophile responsible
for the main cleavage activity. However, they also hint at
an important role for arginines, which are crucial for
DNA binding (4). In order to investigate this further, we
employed the same set of peptides under trapping condi-
tions and demonstrated ﬁrst that the majority of substrate
molecules was trapped in a covalent linkage with the
hook 3 peptides at 50mM NaCNBH3 (Figure 3B).
Substitutions of residues K1, R2, R4 or R6 substantially
reduced but did not completely eliminate complex
Figure 2. Characterization of the AP lyase activity. (A) Creation of AP substrate containing a single abasic site using uracil DNA glycosylase
(UDG). (B) 15% denaturing SDS–PAGE. Four micrograms per lane of each protein was loaded onto the gel. (C) Determination of the chemical
nature of DNA ends generated by HMGA2. Cleavage products obtained with the following E. coli proteins: formamidopyrimidine N-glycosylase
(Fpg), endonucleases III (endo III) and IV (endo IV), as indicated, can be separated from substrates through denaturing polyacrylamide gel
electrophoresis. The 31-mer incubated under the same conditions, but in the absence of protein is shown as control in lane 1. (D) Quantiﬁcation
of AP lyase activities. After electrophoresis and autoradiography, bands corresponding to substrate and products were quantiﬁed and plotted against
the molar protein to DNA ratio.
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lysines still generated a substantial amount of trapped
complexes. Compared with the linker peptide used as con-
trol, only the peptide without arginines failed to generate
detectable complexes, which, taken together, is in agree-
ment with the AP site cleavage data shown in Figure 3A.
We conclude that the AT-hook contains more than one
nucleophile capable of attacking AP sites, and arginines,
in addition to the N-terminal lysine, must be involved.
We have shown so far that hook 3 has AP lyase activity.
We next tested whether hooks 1 and 2, which deviate
slightly from hook 3, also exhibit this cleavage activity.
The results obtained with a second set of peptides clearly
demonstrated that this is indeed the case (Figure 3D).
In addition, using a peptide representing the histidine
tag at the C-terminus of our recombinant HMGA2, we
also show that histidines have no AP site cleavage activity
under these conditions (Figure 3D, right panel).
HMGA2 is also a dRP lyase
Having established that HMGA2 is an AP lyase, we next
examined whether this protein also possesses the related
50-deoxyribosyl phosphate (dRP) lyase activity. To test
this possibility, we employed the same 31-mer oligonu-
cleotide containing a single abasic site. However, the
substrate was 30-labeled and pre-incubation with endonu-
clease IV produced a 50-dRP moiety on the labeled strand
(Figure 4A). In order to stabilize the chemically labile
deoxyribosyl phosphate group and increase separation of
cleaved from non-cleaved dRP lyase products during elec-
trophoresis; the dRP moiety was reacted with BA. The
presence of BA-adducts leads to retardation during elec-
trophoresis when compared with products that lost the
dRP moiety due to a dRP lyase activity (Figure 4B,
lanes 3–4). Using this assay, we established that HMGA
proteins and the AT-hook 3 peptide eﬃciently removed
the dRP moiety. Thus, HMGA proteins act as a dRP
lyase (Figure 4B, lanes 5–12). By contrast the linker pep-
tide connecting HMGA2 hooks 1 and 2 was unable to
cleave dRP substrates (data not shown).
Once a genomic AP site is generated, the next step in
BER involves AP endonucleases and/or AP/dRP lyases
which cleave the DNA backbone at the base lesion.
However, the tautomeric open-ring form of deoxyribose
produced by DNA glycosylases can react very fast with
BA (Figure 4B). It has been shown that BA-adducts inhi-
bit DNA cleavage by mammalian AP endonucleases and
AP lyases (35), and we conﬁrmed that 5mM BA comple-
tely blocked the dRP lyase activity of HMGA2 in vitro
(Figure 4C).
Figure 3. Identiﬁcation of nucleophiles in AT-hook 3. (A) Comparison
of AP site cleavage activities of various hook 3 peptides with a linker
peptide and full-length HMGA2. The hook 3 aa sequence with residues
numbered is displayed in the box. The control reaction lacked any
protein. The positions of the substrate (31-mer) and the cleavage prod-
uct (13-mer) are indicated on the right side. The percentage cleavage
was calculated based on the combined signal intensities from substrate
and product (100%), after subtraction of the background value
obtained with the control. (B and C) Trapping of peptides in a covalent
intermediate complex with the 31-mer AP site substrate. Trapping con-
ditions were ﬁrst optimized in (B) with unmodiﬁed hook 3 and various
concentrations of the trapping salt NaCNBH3, using NaCl as control.
The percentage of trapped complexes was calculated in (C) based on
the combined signal intensities from the 31-mer substrate and the
shifted complex (100%), after subtraction of the background value
obtained with the control. (D) Comparison of AP site cleavage activ-
ities of various peptides containing hook sequences. The aa sequences
of full-length HMGA2 and of the peptides are shown on top of the
cleavage assays. Note that we included two controls; a linker (Linker 1)
and his-tag peptide.
Nucleic Acids Research, 2009,Vol.37, No. 13 4377HMGA2 can be covalently trapped at genomic abasic
sites in vivo
After demonstrating that HMGA2 is an AP and a dRP
lyase, we investigated whether these BER functions play a
bona ﬁde role in human cervical and lung cancer cells,
which exhibit a much reduced expression level of p53
and contain an oncogenic mutation in RAS, respectively.
We employed HeLa and A549 cells, and ﬁrst generated
stable transgenic cell lines which constitutively expressed
HMGA2. Western blot analysis showed that HMGA2 fell
below the detection limit in extracts prepared from paren-
tal cells, but was present in transgenic cells. Since these
were generated by random genome insertion of expression
vectors, we chose three transgenic lines of each parental
line for further analysis to eliminate the possibility that a
particular phenotype is due to insertional mutagenesis
(Figure 5A).
To investigate whether HMGA2 can be covalently
trapped at genomic AP sites using NaCNBH3, parental
A549 cells were ﬁrst challenged with low pH or physiolog-
ical pH as control. DNA puriﬁed from these cells was then
incubated with HMGA2 under trapping conditions, aﬃn-
ity puriﬁed and dot-blotted. The results show that
HMGA2 could only be detected in complex with genomic
DNA isolated from cells that were challenged with low pH
(Figure 5B). This demonstrates that AP sites introduced
in vivo can be cleaved by HMGA2 in vitro. In order to
directly show that HMGA2 was trapped at AP sites
in vivo, we employed A549 (1.6) cells and exposed them
to low pH. Treated cells were morphologically indistin-
guishable from untreated controls, and were harvested
and lysed at neutral pH under either trapping or non-
trapping conditions. Puriﬁed DNA was dot-blotted and
the results clearly showed that a signiﬁcant amount of
HMGA2–DNA complexes was detectable only with geno-
mic fragments harvested under trapping conditions
(Figure 5C). We conclude that cells exposed to low pH
challenge must contain a signiﬁcant number of genomic
AP sites that can be cleaved by HMGA2 in vitro and
in vivo.
We next analyzed cytotoxic eﬀects that might result
from depurination in parental and transgenic cells, and
challenged them for 6min with low pH. After recovery,
FACS analysis of necrotic cells revealed that all transgenic
cell lines were substantially more resistant to low pH
challenge than parental cells (Figure 5D and E).
HMGA2 displays compound selectivity to protect cancer
cells from genotoxicants
Hydroxyurea (Hu) is a frequently used chemotherapeutic
agent for the treatment of proliferative disorders and solid
tumors, and is able to induce base oxidation and depur-
ination (36). We exposed parental and transgenic cells to
Hu for a period of 48h, and determined the fraction of live
cells using FACS analysis. Expression of HMGA2
resulted in signiﬁcant protection against cell death, leading
to a 2–8-fold increase in cell survival (Figure 6A and B).
In order to demonstrate that transgenic cells were not
impaired per se in entering apoptosis, we next exposed
cells to the chemotherapeutic agent paclitaxel, which
is an inhibitor of mitosis and targets tubulin and
the Bcl-2 oncoprotein, instead of DNA (37). When
compared with parental cell lines, none of the HMGA2
transgenic lines displayed a protective phenotype
(Figure 6C and D).
Expression of HMGA2 was recently shown to increase
the cytotoxic eﬀects of DNA double strand breaks
induced by certain topoisomerase type II inhibitors and
the chemotherapeutic agent cisplatin (38). Cisplatin DNA
cross-links are mainly repaired by nucleotide excision
repair (NER), and not through BER. We therefore
tested whether our HMGA2 transgenic lines exhibited a
similar phenotype when treated with cisplatin, and the
results showed that this is indeed the case (Figure 6E).
Hence, the protective eﬀects exerted by HMGA2 seem
to be limited to particular repair pathways.
Figure 4. Characterization of the dRP lyase activity. (A) Strategy for
the creation of the dRP lyase substrate and expected cleavage products.
(B) dRP lyase activity assay. The electrophoretic mobility of the 18-mer
substrate containing the dRP moiety is retarted due to BA-adduct
formation. The observed shift and visible double band veriﬁed that
the HMGA proteins and hook 3 cleaved the substrate. (C)
Quantitative in vitro analysis of BA as an inhibitor of the HMGA2
lyase activity. BA was ﬁrst added to the reaction for 5min, followed by
HMGA incubation for 15min.
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blocked by lyase inhibition
Both AP and dRP lyase activities play central roles in the
initial steps of BER. The DNA methylating agent methyl
methanesulphonate (MMS) has been used frequently to
study this particular repair pathway in mammalian cells.
MMS produces genomic AP sites through the action of
DNA glycosylases, which remove the chemically modiﬁed
bases. In a ﬁrst set of experiments, we exposed parental
HeLa and the respective transgenic cells to 4mM MMS
for 1h, followed by 48h recovery before FACS.
We included here a second HeLa cell line as a control
(EBO) which, like the HMGA2 transgenic lines, expressed
a neomycin marker but lacked the HMGA2 transgene.
The results show that the presence of HMGA2 led to a
signiﬁcant increase in the number of live cells in all trans-
genic cell lines (Figure 7A). Likewise, treatment of paren-
tal and transgenic A549 cells with various MMS
concentrations revealed that HMGA2 always conferred
strong protection against MMS-induced cytotoxicity
(Figure 7B). This result was conﬁrmed by colony forming
assays after MMS treatment (Supplementary Table 1).
In order to demonstrate that protection from MMS-
induced DNA damage observed with transgenic cells
involves HMGA2 lyase activities, we inhibited these
Figure 5. Transgenic HMGA2-overexpressing cancer cell lines and cell viablity after depurination at low pH. (A) Western blot analysis. HMGA2
transgenic cells (A549 derived 1.3, 1.5 and 1.6; and HeLa derived P2, P8 and P19) show various expression levels, using b-actin as internal control.
(B) Dot-blot showing in vitro trapping of HMGA2 on puriﬁed A549 genomic DNA after depurination in vivo. The experimental set-up is described in
the upper panel. (C) Dot-blot showing in vivo trapping of HMGA2 on 1.6 cell genomic DNA due to depurination. The experimental set-up is
described in the upper panel. A control for the amount of DNA loaded is shown above the blot. (D) FACS analysis of A549 necrotic cells (PI+)
determined after 6min depurination at pH 2 and 24h recovery. Data analyzed with Student’s t-test.
 P<0.005.
  P<0.001. (E) FACS analysis of
HeLa necrotic cells (PI+) determined after 6min depurination at pH 3 and 24h recovery. Bars represent mean values with standard deviations
obtained from biological triplicates. Data analyzed with Student’s t-test.
  P<0.001.
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BA. The results show that BA alone had no eﬀect on the
survival of parental or transgenic A549 cells (Figure 7C).
However, pre-treatment with 6mM or 8mM MMS fol-
lowed by exposure to BA not only negated the protection
seen with transgenic cells but sensitized these cells to
MMS treatment (Figure 7B and C). This result was con-
ﬁrmed by colony forming assays (Supplementary Table 2).
We noted that the degree of protection against MMS
did not directly correlate with HMGA2 levels. We rea-
soned that this might be due to the fact that even in
transgenic A549 (1.5) cells, which express HMGA2 at a
comparatively low level, the intracellular amount of
HMGA2 protein might be suﬃcient to eﬃciently cope
with the number of AP sites generated by 10mM MMS.
If so, diﬀerences in protection against MMS between low-
and high-level HMGA2 cells might become apparent only
at higher MMS doses. We therefore exposed A549 (1.5)
and A549 (1.3) cells to increasing concentrations of MMS
and measured cell survival as before. The results clearly
reveal that the protective eﬀect directly correlates with
HMGA2 expression at MMS concentrations above
10mM (Figure 7D).
To conﬁrm that the protective eﬀect against MMS is
not due to the long-term expression of HMGA2 in our
transgenic cell models, colony-forming assays were per-
formed with A549 and HeLa cells exposed to MMS chal-
lenge 48h after transient transfection with HMGA2
expression vectors. HMGA2 transfected cells gave rise to
at least 20% more colonies as compared to CMV-EGFP-
transfected control cells and this diﬀerence increases with
higher concentration of MMS (Figure 7E). In addition,
these diﬀerences originated from the 60% to 70% of
cells successfully transfected, as judged by FACS using
CMV-EGFP-transfected cells before MMS treatment
(data not shown). Together, these results showed that
even a transient presence of HMGA2 protects cells against
MMS-induced DNA damage.
HMGA2 interacts with the BER protein APE1
We next tested the possibility whether HMGA2 interacts
with the cellular BER machinery in vivo. In this context, it
is worth noting that HMGA2 physically interacts with
DNA repair proteins AP endonuclease 1 (APE1) and
Ku70 in vitro (39). The former is a major BER component
in human cells. We used Ni
+ sepharose co-aﬃnity precip-
itation and were able to detect APE1 signals enriched in
1.3 and P2 cell lysates under native conditions, whereas no
signal was detected in lysates from parental cells lacking
tagged HMGA2 (Figure 7F).
HMGA2 protects cells against MMS-induced DNA
strand breaks
The protective eﬀect of HMGA2 against MMS-induced
cytotoxicity and its reversal by the inhibition of AP site
processing through BA aducts indicated that the protein is
directly involved in BER. Thus, HMGA2 should reduce
the number of genomic DNA strand breaks induced by
MMS. To demonstrate this directly, we performed Comet
assays comparing parental A549 with transgenic 1.5 cells,
and parental HeLa with P2 cells after treatment with
0.1mM MMS in suspension culture for 2h without a sub-
sequent recovery period. The results clearly show that
HMGA2 signiﬁcantly reduced the extent of DNA
damage in both transgenic cell lines as measured by tail
moments (Figure 8).
DISCUSSION
We show in this study that HMGA2 and the homologous
HMGA1 proteins have intrinsic dRP/AP lyase activities.
Figure 6. Cell viability of parental and HMGA2 expressing cancer cell
lines after challenge with various compounds. Percentage of live cells
was determined by FACS after staining with Annexin-V ﬂuorescence
and Propidium Iodide. Data analyzed with Student’s t-test.
 P<0.005.
  P<0.001. (A and B) Cells exposed to 100mM Hydroxyurea for 48h.
(C) A549 cells and derivatives exposed treated with 50nM paclitaxel for
48h. (D) HeLa cells and derivatives treated with 20nM paclitaxel for
48h. (E) Cisplatin treatment. Bars charts represent mean values with
standard deviations indicated and obtained from biological assays in
triplicate.
4380 Nucleic Acids Research, 2009, Vol. 37,No. 13Furthermore, we identiﬁed the N-terminal lysine within
the DNA-binding domains as a crucial nucleophile that
attacks AP sites during b elimination. Neighboring argi-
nines can fulﬁll this function as well. Substitutions within
hooks which could compromise or eliminate lyase activ-
ities would almost certainly also aﬀect DNA binding and,
in turn, the functions of HMGA2 as a DNA-architectural
chromatin factor. Based on the fact that the AT-hooks are
almost identical in sequence, substitutions would have to
be introduced into all three hooks simultaneously. In addi-
tion to DNA binding, some of these substitutions may
also interfere with nuclear import and HMGA2–pRB pro-
tein interactions (20,40). Hence, a mutational screen did
not seem a productive approach to distinguish the lyase
activities from the other critical biological functions of
HMGA2.
We presented here several lines of evidence that the
lyase activities do indeed have important biological func-
tions and play a direct role in conferring resistance against
certain DNA-damaging agents. First, HMGA2 was
eﬃciently trapped in a covalent complex with genomic
AP sites in vivo. This indicated that the HMGA2 protein
recognizes and cleaves AP sites within the background of
chromatin. Subsequent to MMS challenge, treatment with
BA sensitized transgenic cells to MMS, thus negating the
protection that was observed when cells were exposed to
MMS only. BA reacts with the deoxyribose moiety at AP
sites and inhibits mammalian AP endonuclease and AP/
dRP lyase activities. We showed that HMGA2 interacts
with APE1 and conclude that HMGA2 confers resistance
to MMS and other AP site-inducing genotoxicants
through a role in BER, which at least in part, involves
HMGA2 lyase activities. This protective eﬀect is directly
correlated with the expression level of HMGA2 at ele-
vated MMS concentrations and protection was also
observed when HMGA2 was only transiently expressed.
Further evidence for an involvement of HMGA2 in BER
repair stems from the result of the Comet assays.
Expression of HMGA2 signiﬁcantly reduced the number
of genomic DNA strand breaks after MMS treatment.
The steady-state number of AP sites in the genome of
mammalian cells is at least 10000. Most of these sites
appear to be processed quickly by APE1, which generates
the 50-dRP moiety (41). Its removal by dRP lyase seems to
Figure 7. HMGA2 expression confers resistance against MMS which can be reversed by co-treatment with the lyase inhibitor BA, and physical
interaction of HMGA2 with APE 1. (A) Percentage of live cells determined by FACS after challenging HeLa cells and derivatives with 4mM MMS
for 1h, followed by 48h recovery. Data analyzed with Student’s t-test.
  P<0.001. (B and C) Percentage of live cells determined by FACS after
challenging A549 cells with MMS at the indicated concentrations for 1h, followed by 48h recovery. Data were normalized to untreated parental and
transgenic cells (100%). BA was added to an additional set of wells during recovery, and DMSO, the solvent for BA, was added to a control set.
Note that BA alone does not aﬀect cell viability. Data analyzed with Student’s t-test.
 P<0.005.
  P<0.001. (D) Percentage of live cells determined
by FACS after challenging 1.3 and 1.5 cell lines with increasing concentration of MMS for 1h, followed by 48h recovery. (E) Percentage of surviving
colonies from HMGA2-transfected cells upon treatment with MMS, with reference to cells transfected with control vector. Data analyzed with
Student’s t-test.
  P<0.001. (F) Western blotting analysis of co-aﬃnity precipitation of cellular APE1 via HMGA2-His in transgenic cells (lanes 3, 4,
7 and 8). Whole cell lysates (wcl) were used as controls (lanes 1, 2, 5 and 6).
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Consequently, the level of dRP lyase activity will directly
aﬀect the cellular repair capacity and sensitivity against
DNA damage that leads to AP sites (42). The level of
DNA polymerase b, the main dRP lyase activity in
human cells, varies substantially in human cancer cells
(43). This scenario is in agreement with our ﬁnding that
an elevated level of HMGA2 protects cancer cells from
DNA-damage-induced cytotoxicity. Mechanistically,
BER involves protein-protein and protein–DNA interac-
tions, which are most likely coordinated to some extent. It
is clear that the level of other BER factors, such as OGG1,
APE1, or the scaﬀold protein XRCC1, may also aﬀect the
repair capacity in a situation where there is an abundance
of dRP lyase molecules (44,45). In agreement with a recent
report on HMGA2 and APE1 interaction in vitro (39), we
demonstrate here that both proteins also interact with
each other inside cells.
Exposure of cells to the chemotherapeutic agent Hu has
been shown to induce base oxidation and depurination
(36). However, the main cytotoxic eﬀect of Hu is attribu-
ted to the inhibition of the enzyme ribonucleotide reduc-
tase, which, in turn, inhibits DNA synthesis during
replication and repair (46). Our results showed that
HMGA2 protects cells from Hu-induced cytotoxicity
and it is conceivable that this involves HMGA2’s novel
activity in AP site processing during BER. However, we
were surprised by the magnitude of protection. This might
indicate that HMGA2 could participate in other aspects of
genome stability; for example, rescue of stalled replication
forks, or the chemical processing of single strand breaks
which will also result from Hu treatment.
Our data showed that HMGA2 confers cellular protec-
tion to three diﬀerent genotoxicants, i.e. Hu, MMS and
low pH. This is not a consequence of the role of HMGA2
as a chromatin factor and transcriptional regulator which
could aﬀect the ability of transgenic cells to enter apopto-
sis. Exposure to the chemotherapeutic agent paclitaxel
revealed no diﬀerence in cytotoxicity compared with
parental cells. In addition, expression of HMGA2 was
recently shown to increase the cytotoxic eﬀects of DNA
double strand breaks induced by certain topoisomerase
inhibitors and the chemotherapeutic agent cisplatin (38).
The latter eﬀect was attributed to the inhibition of the
nucleotide excision repair (NER) gene ERCC1, which is
negatively regulated by HMGA2 (47). It was furthermore
hypothesized that HMGA2 masks certain DNA lesions
from recognition by the NER machinery (48). We con-
ﬁrmed in this study that HMGA2 sensitized cancer cells
to cisplatin, thus providing further proof that the ability of
our transgenic cell models to enter apoptosis was not com-
promised. Taken together, a major conclusion from our
data is that even transient expression of HMGA2 has a
direct supporting role in BER, which involves dRP/AP
lyase activities. This leads to resistance of cancer cells
against certain genotoxicants. In contrast, the presence
of HMGA2 inhibits NER and, thereby, sensitizes cells
to a diﬀerent class of compounds.
It is well established that unrepaired AP sites are
mutagenic (49). Since HMGA2 is found at high levels
in many human neoplastic and pluripotent hES cells,
Figure 8. Quantiﬁcation of DNA damage via Comet assays. (A and C)
The Olive tail moment from every cell present in a given sample image
was determined until 100 cells were scored from each sample. The
average tail moment values were then calculated for each sample and
comparisons between the two treated and untreated samples analyzed
with Student’s t-test, which revealed signiﬁcant diﬀerences only between
treated samples (P<0.05). (B and D) Representative images obtained
with treated and untreated A549 and HeLa samples, respectively, as
indicated.
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through its associated lyase activities, contributes to
lower mutation rates. From an evolutionary point of
view, this is obviously most important for metabolically
active ES cells which replicate and transcribe their
genomes at a high rate and eventually produce germ
cells. In fact, recent data showed that genes involved in
diﬀerent types of DNA repair are signiﬁcantly upregulated
in hES cells when compared with diﬀerentiated progeny
cells (50). We found that the expression level of HMGA2
in hES cells is comparable with that of our transgenic
A549 (1.5) and HeLa (P8) cells (Li and Dro ¨ ge, unpub-
lished results). In this context it is perhaps interesting to
note that HMGB1, HMGN1 and HMGN2 proteins are
also expressed in hES cells (12). Prasad et al. (31) recently
showed that HMGB1 possesses dRP lyase activity, and we
detected very robust AP and dRP lyase activities for
HMGN1 and HMGN2 (Summer and Dro ¨ ge, unpublished
results). It emerges, therefore, a possible scenario in which
these abundant non-histone chromatin-modifying factors
play a hitherto unrecognized, direct role in the mainte-
nance of genome stability.
Our ﬁnding that HMGA2 protects cancer cells from
certain DNA-damaging agents used in cancer treatment
has important implications for disease diagnosis, choice of
treatment regimens, and the future development of anti-
cancer drugs (51). First, we think it will now become even
more important than previously suggested (21) to type
malignant tumors, and, whenever possible, the replenish-
ing cancer stem cell compartment with respect to the
HMGA2 status. This knowledge will impact on the
choice of the most suitable chemotherapeutic agents.
Since we have shown that HMGA1 isoforms also exhibit
dRP/AP lyase activities in vitro, we anticipate that the
protective eﬀect observed for HMGA2-expressing cancer
cells will also be detectable for tumors that show an ele-
vated level of HMGA1 proteins. In that respect, it is note-
worthy that HMGA1 was recently shown to belong to a
class of proteins that are speciﬁcally phosphorylated upon
ATM/ATR activation through DNA damage (52). In the
future it will be important to investigate how posttransla-
tional modiﬁcations aﬀect the newly discovered lyase
activities of HMGA proteins.
We have provided ﬁrst evidence obtained with MMS
and BA treatment that a combination therapy, which
targets HMGA2’s role in BER and includes established
genotoxicants could prove particularly eﬀective against
cancer cells otherwise resistant to chemotherapy.
Secondly, anti-cancer therapy targeting HMGA2 will
likely not aﬀect normal adult cells which lack detectable
HMGA2 levels, but exclusively target HMGA2 expressed
in malignant cells. This novel class of anti-cancer com-
pounds could act by interfering with DNA-binding (21)
and/or protein–protein interactions in BER involving
HMGA2.
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